Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. has proposed a 2024 Employee Stock Ownership Plan (ESOP) aimed at aligning the interests of employees and shareholders, enhancing corporate governance, and promoting long-term sustainable development [3][12][16]. Group 1: Plan Overview - The ESOP is designed to comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [3][12]. - The plan will be managed by a dedicated committee, which will represent the interests of the participants and ensure compliance with legal requirements [9][25]. - The total amount to be raised through the plan is capped at RMB 37.7868 million, with each unit priced at RMB 1.00 [4][14]. Group 2: Participants and Structure - The plan will involve a maximum of 35 employees, including directors (excluding independent directors), supervisors, senior management, and core business personnel [4][13]. - The stock purchase price is set at RMB 26.15 per share, which is based on a fair valuation considering the company's performance and market conditions [15][16]. - The total shares allocated under the plan will not exceed 1.445 million shares, representing approximately 0.35% of the company's total share capital [5][18]. Group 3: Lock-up and Vesting - The plan has a duration of 48 months, with shares unlocking in two phases: 50% after 12 months and the remaining 50% after 24 months [6][21]. - The unlocking of shares is contingent upon the company's performance meeting specific revenue growth targets, which are set against the 2023 revenue of RMB 2.709 billion [22][23]. Group 4: Financial Management and Compliance - The company will not provide any financial assistance to participants, ensuring that all funding comes from employees' legal salaries and self-raised funds [4][14]. - The management committee will oversee the daily operations of the ESOP, ensuring that all actions comply with the established guidelines and protect the rights of the participants [25][30]. - The plan includes provisions for adjusting the stock purchase price in the event of corporate actions such as stock splits or dividends [16][17].

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. reported on the management and usage of raised funds for the first half of 2025, detailing the total amount raised, its allocation, and the current balance of funds [1][3]. Fundraising Overview - The total amount raised from the initial public offering (IPO) was approximately RMB 3.60 billion, with a net amount of RMB 3.31 billion after deducting issuance costs [1][3]. - As of December 31, 2024, the balance of the raised funds was RMB 1.82 billion, which decreased to RMB 1.67 billion by June 30, 2025, after accounting for usage and interest income [1][2]. Fund Usage and Management - The company has established a fundraising management system to ensure proper storage and usage of the funds, adhering to relevant regulations [1][3]. - The company signed tripartite and quadripartite agreements with its sponsor and banks to regulate the management of the raised funds [1][3]. Fund Allocation - The actual usage of the raised funds for the reporting period was RMB 39.11 million, with a cumulative total of RMB 1.57 billion used to date [3][4]. - There were no instances of using idle funds for temporary working capital or for repaying bank loans during the reporting period [3][4]. Project Status and Adjustments - The company completed the investment projects "BGI Intelligent Manufacturing Information System Construction" and "BGI Intelligent Manufacturing Marketing Service Center Construction," leading to a decision to permanently supplement working capital with the remaining funds [3][4]. - The timeline for the "BGI Intelligent Manufacturing and R&D Base Project" has been extended to March 2026 due to construction delays [3][4]. Financial Management - The company has engaged in cash management for idle funds, investing in high-security and liquid financial products, with a total of RMB 868 million allocated to various structured deposits [2][4]. - The company reported an investment income of RMB 16.28 million from these financial products, which has been returned to the fundraising account [4][6].

Core Viewpoint - The company has announced a stock incentive plan involving the grant of 6.555 million restricted stocks, accounting for 1.58% of the total share capital, aimed at enhancing corporate governance and retaining talent [1][3][5]. Summary by Sections Stock Incentive Plan Purpose and Principles - The purpose of the incentive plan is to improve corporate governance, establish a long-term incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees [1][3]. Stock Incentive Method and Source - The incentive method involves the issuance of second-class restricted stocks, sourced from repurchased shares or newly issued A-shares directed to incentive recipients [3][4]. Number of Rights Granted - The plan proposes to grant a total of 6.555 million restricted stocks, representing 1.58% of the company's total share capital of 41.56376 million shares [1][5]. Determination of Incentive Recipients - Incentive recipients include directors, senior management, core technical personnel, and key business staff, excluding independent directors and supervisors [4][5]. Distribution of Restricted Stocks - The distribution of restricted stocks among recipients is detailed, with 97.25% allocated to business backbone personnel [5]. Validity Period of the Incentive Plan - The plan is valid from the date of stock grant until all granted stocks are vested or become invalid, with a maximum duration of 36 months [6]. Granting and Vesting Conditions - The grant price for the restricted stocks is set at 26.15 yuan per share, with specific conditions for granting and vesting based on performance metrics [9][10]. Performance Assessment Metrics - The performance assessment will consider revenue growth excluding impacts from public health events, with specific targets set for the years 2024 and 2025 [12][13]. Accounting Treatment and Impact on Financial Performance - The plan's implementation will affect the company's accounting costs, with estimated expenses to be amortized over the vesting period [23][24]. Rights and Obligations of the Company and Recipients - The company retains the right to cancel unvested stocks if performance conditions are not met, while recipients must fulfill tax obligations related to the granted stocks [25][26].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. plans to revise its 2024 restricted stock incentive plan and employee stock ownership plan to enhance employee motivation and align with the company's strategic goals in the context of the evolving market environment [10][11]. Summary by Sections Incentive Plan Overview - The incentive plan involves granting restricted stocks to key personnel, including directors, senior management, and core technical staff, to align their interests with the company's long-term performance [1][4]. Necessary Procedures - The company has followed necessary procedures, including board meetings and shareholder approvals, to implement the incentive plan and employee stock ownership plan [5][6][7]. Revision Reasons - The revision is driven by the need to adapt to changes in the external environment and to focus on increasing market share in the gene sequencing equipment sector, which is critical for long-term revenue growth [10][11]. Revised Performance Metrics - The revised performance metrics will include non-related party gene sequencing instrument sales as a key performance indicator, aiming to enhance the company's competitive position and employee engagement [11][12]. Conclusion - The independent financial advisor confirms that the revisions to the incentive plan and employee stock ownership plan have met the necessary review and disclosure obligations and are pending shareholder approval for implementation [14][15].

Core Viewpoint - The company has revised its 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan to enhance employee motivation and align with its strategic goals, particularly focusing on increasing market share in the gene sequencing industry [1][11]. Group 1: Decision Process and Disclosure - The company has completed the necessary decision-making procedures and disclosures for the 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan, which require approval from the shareholders' meeting to be implemented [2][12]. - The supervisory board has verified the related matters of the incentive plan and provided relevant opinions [4][11]. Group 2: Reasons for Revision - The revision aims to adapt to changes in the external environment and the company's actual situation, adding performance assessment indicators related to the sales volume of gene sequencers excluding related parties [6][10]. - The company believes that capturing market share in gene sequencer sales is crucial for driving subsequent reagent sales and revenue growth [6][10]. Group 3: Revised Content - The revised performance assessment indicators now include the sales volume of gene sequencers excluding related parties, with specific targets set for the first and second vesting periods [7][9]. - The performance completion rates and corresponding vesting ratios have been adjusted to reflect the new assessment criteria [8][9]. Group 4: Impact of Revisions - The revisions are expected to effectively motivate employees and support the company's strategic and operational goals without adversely affecting its financial status or operational performance [11][12]. - The adjustments are designed to enhance the company's competitiveness and market coverage, particularly in the context of increasing pressure from macroeconomic factors and competition [10][11].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. plans to implement a restricted stock incentive plan for 2024 to enhance corporate governance, attract and retain talent, and align the interests of shareholders, the company, and employees for long-term development [1][2]. Group 1: Assessment Objectives and Principles - The purpose of the assessment is to improve corporate governance and establish an incentive mechanism to ensure the achievement of the company's strategic and operational goals [2]. - The assessment must adhere to principles of fairness, openness, and justice, linking the incentive plan closely with the performance and contributions of the incentivized individuals [2] Group 2: Assessment Scope and Institutions - The assessment applies to all participants in the incentive plan, including directors, senior management, core technical personnel, and key business staff, excluding independent directors and supervisors [2]. - The Board's Compensation and Assessment Committee leads the assessment, while the Human Resources Center is responsible for implementation and data collection [2][5]. Group 3: Assessment Indicators and Standards - The assessment period for the incentive plan is set for the fiscal years 2024-2025, with annual evaluations based on the company's revenue growth rate and sales growth of sequencing instruments [3][4]. - The performance targets are based on the 2023 revenue of 2.709 billion yuan and the sales of 532 sequencing instruments, with specific growth rates defined for assessment [3][4]. Group 4: Individual Performance Assessment - Individual performance assessments will be conducted according to existing company regulations, with results determining the actual number of shares allocated to each incentivized individual [4]. - The performance rating system categorizes results into five levels (S, A, B, C, D), with corresponding allocation ratios for shares based on performance [4]. Group 5: Assessment Procedures and Results Management - The Human Resources Center is responsible for maintaining assessment results and preparing performance reports for the Compensation and Assessment Committee [5]. - Assessment results are confidential and archived for five years, with provisions for dispute resolution and appeals by assessed individuals [5]. Group 6: Additional Provisions - The plan is subject to approval by the company's shareholders and will be implemented following the effective date of the 2024 incentive plan [6].

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. (referred to as "BGI Intelligent Manufacturing" or "the Company") has established a revised employee stock ownership plan for 2024, aiming to enhance employee motivation and align their interests with those of the company and its shareholders [1][29]. Summary by Sections Chapter 1: General Provisions - The employee stock ownership plan is formulated in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1]. Chapter 2: Formulation of the Stock Ownership Plan - The plan adheres to principles of legality, voluntary participation, and risk-bearing by participants [2][3]. - Eligible participants include up to 35 employees, specifically directors (excluding independent directors), supervisors, senior management, and core business personnel [2][3]. - The total funding for the plan is capped at RMB 37.7868 million, with a subscription unit priced at RMB 1.00 per share, and a maximum of 37.7868 million shares available for subscription [3][4]. Chapter 5: Asset Composition and Rights Distribution of the Stock Ownership Plan - The assets of the plan include the company's stock, cash deposits, and other investments [23]. - Upon the expiration of the lock-up period, the management committee will determine the method of disposing of the stock and distributing assets to participants [24]. Chapter 6: Changes, Termination, and Rights Disposal of the Stock Ownership Plan - The plan may be terminated if there is a change in the actual controller of the company or in the event of a merger or division [25]. - Any changes to the plan during its duration require approval from the majority of participants [25]. Chapter 8: Lock-up Period and Performance Assessment - The lock-up period for the stock is set at 12 months and 24 months, with 50% of the shares unlocking at each interval [9]. - Performance assessments will be based on the company's revenue growth and sales of gene sequencers, with specific targets set for each assessment period [11][12]. Chapter 9: Management of the Stock Ownership Plan - The management committee, elected by the participants, will oversee the plan's implementation and ensure compliance with relevant regulations [16][18]. - The company board is authorized to handle all matters related to the stock ownership plan, including its establishment, changes, and termination [21]. Chapter 10: Rights and Obligations of the Company and Participants - Participants have the right to vote and receive dividends, while they are obligated to comply with the plan's regulations [22]. - The company is responsible for supporting the plan and ensuring its compliance with laws and regulations [22]. Chapter 11: Legal Compliance and Interpretation - The plan will be interpreted by the company's board and must be approved by the shareholders' meeting before implementation [28]. - In case of conflicts with new regulations, the latest legal provisions will prevail [28].

Core Insights - BGI Genomics (688114) reported strong growth in its three main business segments: long-read sequencing (SEQALL), intelligent automation (GLI), and multi-omics (OMICS) despite challenging external conditions [1][2] - The company achieved a record sales volume of over 700 long-read sequencers in the first half of 2025, marking a significant year-on-year increase of 60.35% [1] - The G99 sequencer demonstrated strong competitive advantages in clinical applications, with reagent revenue increasing by 21.97% [1] Segment Summaries Long-Read Sequencing (SEQALL) - Sales volume exceeded 700 units, achieving a historical high for the same period [1] - The market share for nanopore sequencers in the domestic bidding market doubled compared to the previous year [1] - The E25 model showed exceptional performance with equipment revenue increasing by 361.44% and reagent revenue by 585.91% [1] Intelligent Automation (GLI) - Revenue for GLI reached 112 million yuan, with over 130 new sales [2] - The integration of artificial intelligence technology in life science tools has been deepened, with the launch of the self-developed PrimeGen [2] Multi-Omics (OMICS) - Adjusted revenue for OMICS experienced a significant growth of over 40% year-on-year [2] - The cell-omics platform is expanding into overseas markets through product upgrades and a collaborative marketing strategy [2] Strategic Outlook - BGI Genomics is positioned to expand its leading advantage amid the domestic replacement trend, supported by favorable policies and a robust technological barrier [2]

Group 1 - The core business revenue for the first half of 2025 reached 1.091 billion yuan, with a net profit attributable to the parent company reducing losses by 65.28% year-on-year [1] - The long-read sequencing business saw over 700 new instrument sales, a year-on-year increase of 60.35%, marking a historical high for the same period [1] - The company achieved a 37.55% year-on-year reduction in net profit loss after deducting non-recurring items [1] Group 2 - The company has reduced its operating expenses (excluding financial costs) to 827 million yuan, a decrease of 17.04% compared to the same period last year [1] - The company collaborates with over 50 suppliers to enhance core material efficiency, leading to a 25% overall improvement in the supply chain [1] - The global spare parts delivery timeliness rate has improved to 90%, with the China region achieving 91.04%, maintaining a 72-hour delivery cycle [1] Group 3 - The company is advancing its laboratory intelligent automation (GLI) business by leveraging artificial intelligence technology to reconstruct its automation processes [2] - An AI closed-loop solution covering the entire "Design-Build-Test-Learn" process has been developed, significantly compressing the traditional research and development cycle [2] - The transition from manual experience-based decision-making to data-driven approaches in laboratories is being accelerated through these innovations [2]

Core Insights - Huada Zhizao reported a significant reduction in net loss by 65.28% year-on-year for the first half of 2025, with main business revenue reaching 1.091 billion yuan [1] - The company achieved a historical high in instrument sales, with over 700 units sold, marking a 60.35% increase year-on-year [1] - Operational efficiency improved, with a 37.55% reduction in net loss after deducting non-recurring items [1] Business Performance - Main business revenue for the first half of 2025 was 1.091 billion yuan, with a notable reduction in net loss [1] - The company’s operating expenses (excluding financial costs) decreased by 17.04% to 827 million yuan [1] - The core long-read sequencing business remains a key growth driver for the company [1] Supply Chain and Production - The company collaborated with over 50 suppliers to enhance core material efficiency, achieving a 25% improvement in overall supply chain efficiency [1] - Global spare parts delivery rate improved to 90%, with the China region reaching 91.04% [1] - The company maintains a leading position in the industry with a 72-hour delivery cycle [1] Technological Advancements - Huada Zhizao is advancing its laboratory automation business through AI technology, restructuring its operations to enhance efficiency [2] - The company developed an AI closed-loop solution covering the entire "Design-Build-Test-Learn" process, significantly reducing R&D cycles [2] - The integration of AI tools supports a transition from manual decision-making to data-driven processes in laboratories [2]